MGTA has been the subject of several other research reports. Goldman Sachs Group restated a neutral rating and issued a $18.00 price target on shares of Magenta Therapeutics in a report on Friday, December 6th. ValuEngine cut Magenta Therapeutics from a hold rating to a sell rating in a report on Wednesday, November 20th. Zacks Investment Research upgraded Magenta Therapeutics from a sell rating to a hold rating in a report on Tuesday, February 11th. BTIG Research assumed coverage on Magenta Therapeutics in a report on Friday, December 6th. They issued a buy rating and a $20.00 price target for the company. Finally, Cowen restated a buy rating on shares of Magenta Therapeutics in a report on Monday, January 13th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $17.75.
MGTA opened at $14.00 on Thursday. The stock has a market capitalization of $545.85 million, a price-to-earnings ratio of -7.14 and a beta of 3.35. The business has a 50-day moving average of $13.40 and a two-hundred day moving average of $11.98. Magenta Therapeutics has a 12 month low of $8.78 and a 12 month high of $21.00.
Several large investors have recently modified their holdings of MGTA. Bank of Montreal Can lifted its position in Magenta Therapeutics by 57.3% during the 4th quarter. Bank of Montreal Can now owns 2,652 shares of the company’s stock worth $40,000 after acquiring an additional 966 shares in the last quarter. Metropolitan Life Insurance Co NY acquired a new position in Magenta Therapeutics during the 3rd quarter worth approximately $76,000. Citigroup Inc. lifted its position in Magenta Therapeutics by 248.7% during the 4th quarter. Citigroup Inc. now owns 6,876 shares of the company’s stock worth $104,000 after acquiring an additional 4,904 shares in the last quarter. Ikarian Capital LLC acquired a new position in Magenta Therapeutics during the 4th quarter worth approximately $131,000. Finally, Evoke Wealth LLC acquired a new position in Magenta Therapeutics during the 3rd quarter worth approximately $186,000. Institutional investors and hedge funds own 65.41% of the company’s stock.
About Magenta Therapeutics
Magenta Therapeutics, Inc, a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases.
See Also: Overbought
Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.